NCT01954043View on ClinicalTrials.gov

A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

December 20, 2013

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions
Cancer
Interventions
DRUG

Dabrafenib 150 mg twice a day (BID)

Dabrafenib dosed at 150mg twice a day from Day 1 to the morning of Day 29

DRUG

Rabeprazole 40 mg once daily (OD)

Rabeprazole dosed at 40mg each morning on Days 16 to 19

DRUG

Rifampin 600 mg OD

Rifampin dosed at 600mg each morning on Days 20 to 29

Trial Locations (6)

3004

GSK Investigational Site, Melbourne

3084

GSK Investigational Site, Heidelberg

75201

GSK Investigational Site, Dallas

85338

GSK Investigational Site, Goodyear

98405

GSK Investigational Site, Tacoma

W1G 6AD

GSK Investigational Site, London

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01954043 - A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors | Biotech Hunter | Biotech Hunter